MYGN

Business Context and Reporting Period

Company: Myriad Genetics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2007
Overview: Myriad is a biotechnology company focused on molecular diagnostics and therapeutic drug development. The company operates three segments: Research, Molecular Diagnostics, and Drug Development. It has not yet achieved profitability and relies on cash reserves and equity financing to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 38% year-over-year, driven primarily by a 44% increase in molecular diagnostic revenue ($145.3M vs $100.6M). This growth was attributed to increased testing volumes and wider market acceptance.
• Expense Increases:
  • R&D Expenses: Increased 20% to $100.7 million, primarily due to costs associated with Phase 3 clinical trials for Flurizan (Alzheimer's) and Phase 2 trials for Azixa (brain tumors).
  • Selling, General & Administrative (SG&A): Increased 51% to $73.3 million. Drivers included higher sales commissions, headcount expansion, bad debt expense ($3.6M increase), and non-cash share-based compensation ($2.9M increase).
• Liquidity: Cash and marketable securities increased by $80.6 million (35%) to $308.3 million. This was fueled by a $105.3 million net proceeds from a public stock offering in February 2007 and strong operating cash generation from diagnostics, partially offset by clinical trial expenditures.
• Profitability: While the net loss narrowed slightly to $35.0 million from $38.2 million, the operating loss widened to $47.7 million due to increased operating expenses.

Guidance, Outlook, and Risks

• Outlook: Management expects to incur losses for at least the next several years due to the expansion of drug discovery, clinical trials, and facility expansion. The company believes its current capital resources are sufficient to fund operations for at least the next two years.
• Key Clinical Programs:
  • Flurizan: Two Phase 3 trials for Alzheimer's disease are ongoing (enrollment complete).
  • Azixa: Three Phase 2 trials for brain tumors are ongoing.
  • MPC-2130 & MPC-0920: In Phase 1 trials for hematologic cancers and thrombosis, respectively.
• Risks & Contingencies:
  • Regulatory Approval: Success depends heavily on FDA approval of therapeutic candidates; failure in late-stage trials could materially harm the business.
  • Reimbursement: Revenue depends on third-party payors (insurance/Medicare) covering diagnostic tests and future drugs.
  • Intellectual Property: The company relies on patents and licenses (e.g., BRCA1/BRCA2 from University of Utah); litigation or invalidation could impact commercialization.
  • Single Facility: All molecular diagnostic testing is performed at a single CLIA-certified facility in Salt Lake City, creating operational risk.

Investor Verification Checklist

• Cash Runway: Verify if the $308.3 million cash balance remains sufficient given the accelerating burn rate from Phase 3 trials.
• Clinical Trial Results: Monitor upcoming data readouts for Flurizan (Alzheimer's) and Azixa (brain tumors), as these are critical to future valuation.
• Reimbursement Status: Confirm continued coverage and pricing stability for key diagnostic products (BRACAnalysis, COLARIS) with major payors.
• Patent Expirations: Review the timeline for key patent expirations, particularly the BRCA1/BRCA2 licenses (expiring 2015-2018).
• Bad Debt Trends: Assess the increasing bad debt expense ($5.65M in 2007 vs $2.11M in 2006) and its impact on net revenue.